WO2011058366A1 - Use of bethanechol for treatment of xerostomia - Google Patents
Use of bethanechol for treatment of xerostomia Download PDFInfo
- Publication number
- WO2011058366A1 WO2011058366A1 PCT/GB2010/051887 GB2010051887W WO2011058366A1 WO 2011058366 A1 WO2011058366 A1 WO 2011058366A1 GB 2010051887 W GB2010051887 W GB 2010051887W WO 2011058366 A1 WO2011058366 A1 WO 2011058366A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bethanechol
- xerostomia
- treatment
- oral
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to the treatment of salivary gland dysfunction through the topical application of bethanechol to the oral mucosa.
- Xerostomia can be defined as the subjective sensation of dryness of the mouth. This is usually the result of a decrease in the volume of saliva secreted but may also be due to a change in composition of saliva.
- Salivary gland hypofunction is defined as demonstrable reduction in either whole or individual gland flow rates. Salivary gland dysfunction has been used as an umbrella term to describe patients with xerostomia and/or salivary gland hypofunction. The prevalence of xerostomia in the general population is between 22-26% and is more common in patients with chronic illness, for example in the palliative care population the prevalence is between 82-83%. The most common cause for salivary gland hypofunction is drug treatment; another cause is Sjogrens syndrome.
- Xerostomia is an important condition in cancer patients. In head and neck cancer patients, xerostomia arises from collateral radiation damage to the salivary glands. As many as 95% of head and neck cancer patients suffer significant xerostomia, although head and neck cancer represents less than 5% of all cancers. Xerostomia is also a problem in the broader cancer population. These patients suffer xerostomia principally as a result of the medications they receive.
- cytotoxic chemotherapy agents such as 5-fluorouracil, paclitaxel, platinum compounds and busulphan, antineoplastic hormonal agents including anastrozole and bicalutamide
- concomitant medications not specifically given for cancer but common especially in advanced cancer patients, such as anti-depressants, opioid painkillers, antihistamines, corticosteroids, H2 blockers, hypnotics and many others.
- Xerostomia has been reported to be the fourth commonest side-effect of chemotherapy and the third most distressing (Zanni, Pharmacy Times August, 2007).
- the management of salivary gland hypofunction involves treatment of the cause, symptomatic treatment and treatment of the complications.
- Symptomatic treatment involves the use of saliva substitutes or saliva stimulants.
- a number of pharmacological agents have been used as salivary stimulants, including yohimbine and nicotinamide.
- the most widely used are parasympathomimetic drugs, choline esters or anticholinesterase drugs.
- the most well known is pilocarpine which acts primarily on muscarinic receptors. Muscarinic agonists when administered systemically tend to produce side effects including sweating and cardiovascularchanges.
- Bethanechol chloride also called carbamyl-methylcholine chloride
- carbamyl-methylcholine chloride is a known drug which has been used clinically for many years. It is available in tablets and as an injection and is used as a stimulant of the smooth muscle of the gastrointestinal tract, and in particular the urinary bladder. It can also be of value in certain cases of postoperative abdominal distension and gastroparesis. It is administered orally, preferably on an empty stomach in order to minimise nausea and vomiting.
- an oral dosage of 10-50 mg of bethanechol chloride 3-4 times daily is recommended.
- bethanechol chloride given at 25 mg four times a day can cause significant side-effects, such as abdominal cramping, blurred vision, fatigue and an increase in urinary frequency.
- the drug has also been administered by subcutaneous injection, however, parenteral dosage forms are no longer available in the USA. It has been reported that a severe cholinergic reaction is likely to occur if it is given by the i.v. or i.m. routes. Severe reactions have also been reported after subcutaneous injection.
- Bethanechol is contraindicated in patients with hyperthyroidism, peptic ulcer, latent or active bronchial asthma, coronary artery disease, mechanical obstruction of the Gl tract or bladder neck, marked vagotonia, epilepsy, parkinsonism, spastic Gl disturbances, peritonitis or acute inflammatory conditions of the Gl tract, pronounced bradycardia or hypotension or vasomotor instability.
- the safety and efficacy of bethanechol in paediatric patients have not been established.
- drug permeability across buccal tissue is dependent upon physicochemical properties of the drug, such as lipophilicity, molecular weight, and degree of ionisation at physiological pH.
- physicochemical properties of the drug such as lipophilicity, molecular weight, and degree of ionisation at physiological pH.
- transcellular intracellular, passing through the cell
- paracellular intercellular, passing around the cell.
- Permeation has been reported to be mainly by the paracellular route through the intracellular lipids produced by membrane-coating granules; however, the route taken depends upon the physicochemical properties of the drug.
- a compound with a Log P value of less than 0 or less than 1 is usually considered too hydrophilic to be a drug candidate, particularly if it needs to cross lipophilic biological membranes for its activity.
- bethanechol chloride is a quaternary ammonium compound, it is very polar in nature and has a high aqueous solubility (hydrophilic) and a calculated log P value of around -4.0. This is one of the lowest values reported in the literature for a clinically used pharmaceutical agent. Consistent with these physicochemical properties, bethanechol does not significantly penetrate into the CNS at therapeutic doses and is only poorly absorbed from the Gl tract.
- This invention relates to the use, preferably in man, when administered locally to the oral mucosa, of bethanechol, e.g. as the chloride, for the treatment of xerostomia.
- bethanechol chloride is unexpectedly found to be an effective treatment of the condition. This is especially surprising, given that the physicochemical properties of bethanechol chloride are such that it is very difficult to consider using the drug for topical applications where passage of the drug across mucosal membranes would be required for activity.
- a novel formulation is in the form of a package containing, and from which can be dispensed, a liquid or semi-solid formulation comprising bethanechol.
- bethanechol is typically administered via the buccal route with the intention of providing a direct action on the salivary glands, thus resulting in an improvement of conditions associated with xerostomia.
- the administered dose of bethanechol is held within the buccal cavity for a specified period of time in order to facilitate a local action on the minor salivary glands.
- the buccal contents are then swallowed such that any drug not absorbed through the buccal mucosa has the opportunity to gain entry to the systemic circulation via gastrointestinal absorption, and this achieves a secondary stimulation of salivary flow including from the major glands.
- the period of time that the formulation is held in the mouth before swallowing may be from 30 seconds to 5 minutes, preferably 1 to 3 minutes, more preferably 2 minutes.
- a formulation of the invention is typically in a single unit dose form. It may be packaged as, e.g. a sachet, vial, blow-fill seal container, multidose container with separate doses administered manually, for example using a syringe, multidose container with unit dose dispenser, e.g. unidose pump or spray, semi-solid in tube, from which an appropriate amount can be extruded.
- the formulation which will typically be sterile, for therapeutic use, preferably comprises a self-preserving system (e.g. ethanol or other alcohol) and/or includes an appropriate preservative.
- the dosing volume for a liquid or semi solid formulation is typically between 0.1 ml and 1.0 ml, preferably 0.25 ml to 0.75 ml, more preferably 0.3 ml to 0.6 ml.
- the bethanechol may be present in the formulation as a saturated solution.
- buccal bioadhesive systems which may be tablets, patches, films, semisolids, liquids and particulates.
- Semi-solid formulations include gels and ointments. Appropriate dosage levels may be determined by any suitable method known to one skilled in the art.
- Preferable doses (single administration) of bethanechol chloride are in the range of 1 mg to 50 mg, preferably 2 mg to 25 mg and more preferably 3 mg to 9 mg. More than one administration may be given each day. It may be advantageous to combine or co-administer a product of the invention with other classes of drug.
- Drugs which may be co-administered include, but are not limited to, acetylcholinesterase inhibitors.
- bethanechol chloride for buccal administration was prepared as a saturated solution in a solvent mixture comprising PEG 400, glycerol, ethanol and sodium phosphate buffer.
- Specific solvent amounts were 30% PEG 400, 30% glycerol, 20% ethanol with 20% phosphate buffer (formed by mixing 50 ml of 0.1 M sodium phosphate monobasic (monohydrate) with sufficient 0.1 M sodium phosphate dibasic (heptahydrate) until a pH of 5.5 was achieved).
- Bethanechol chloride was present at up to 33%.
- This weight represents 20% of the final formulation.
- the amounts of ethanol, glycerol and PEG 400 were calculated to make a solution containing 30% PEG 400, 30% glycerol, 20% ethanol and 20% buffer and bethanechol.
- the solution was then mixed using the magnetic flea for 30 minutes at room temperature.
- two further aliquots of bethanechol chloride were added with further mixing, resulting in a viscous clear solution with a small amount of undissolved bethanechol being present.
- the pH of the final formulation was 6.7.
- the left carotid artery was cannulated for recording blood pressure and heart rate, and the left jugular vein cannulated for drug administration.
- a Parafilm ball was inserted into the back of the oral cavity to prevent the loss of solution into the oesophagus and airways.
- T -10 minutes a cotton wool ball was inserted into the oral cavity and 10 minutes later it was removed and excess saliva wiped away.
- T 0 minutes physostigmine (1 %, 10 microlitres each on left and right sides) or bethanechol (10 microlitres each on left and right sides) were instilled using a pipette.
- a cohort of approximately 20 patients with xerostomia is randomised to receive either placebo or bethanechol formulation or vice versa with at least 3 days washout between the treatment segments.
- Each treatment is given as a small volume (approximately 0.5 ml) solution to be retained against the buccal mucosa for 1 to 2 minutes and then swallowed.
- Clinical investigations include vital signs, haematology/chemistry and appearance of the buccal mucosa.
- Efficacy measurements include salivary flow and composition of major and minor glands using standard techniques (see e.g.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2780256A CA2780256A1 (en) | 2009-11-12 | 2010-11-11 | Use of bethanechol for treatment of xerostomia |
NZ599880A NZ599880A (en) | 2009-11-12 | 2010-11-11 | Use of bethanechol for treatment of xerostomia |
JP2012538414A JP5595513B2 (en) | 2009-11-12 | 2010-11-11 | Use of bethanechol for the treatment of xerostomia |
DK10779033.9T DK2498771T3 (en) | 2009-11-12 | 2010-11-11 | USE OF BETHANECHOL FOR THE TREATMENT OF XEROSTOMY |
ES10779033.9T ES2443847T3 (en) | 2009-11-12 | 2010-11-11 | Use of betanecol for the treatment of xerostomia |
PL10779033T PL2498771T3 (en) | 2009-11-12 | 2010-11-11 | Use of bethanechol for treatment of xerostomia |
MX2012005456A MX2012005456A (en) | 2009-11-12 | 2010-11-11 | Use of bethanechol for treatment of xerostomia. |
RS20140010A RS53124B (en) | 2009-11-12 | 2010-11-11 | Use of bethanechol for treatment of xerostomia |
US13/505,668 US9149454B2 (en) | 2009-11-12 | 2010-11-11 | Use of bethanechol for treatment of xerostomia |
EP10779033.9A EP2498771B1 (en) | 2009-11-12 | 2010-11-11 | Use of bethanechol for treatment of xerostomia |
BR112012011086A BR112012011086A2 (en) | 2009-11-12 | 2010-11-11 | use of betanecol for xerostomia treatment |
EA201270619A EA022040B1 (en) | 2009-11-12 | 2010-11-11 | Use of bethanechol for treatment of xerostomia |
AU2010317747A AU2010317747B2 (en) | 2009-11-12 | 2010-11-11 | Use of bethanechol for treatment of xerostomia |
SI201030484T SI2498771T1 (en) | 2009-11-12 | 2010-11-11 | Use of bethanechol for treatment of xerostomia |
CN201080061277.5A CN102711752B (en) | 2009-11-12 | 2010-11-11 | Use of bethanechol for treatment of xerostomia |
IL219613A IL219613A (en) | 2009-11-12 | 2012-05-06 | Bethanechol for buccal administration for use in the treatment of xerostomia |
ZA2012/03289A ZA201203289B (en) | 2009-11-12 | 2012-05-07 | Use of bethanechol for treatment of zerostomia |
HRP20140020AT HRP20140020T1 (en) | 2009-11-12 | 2014-01-07 | Use of bethanechol for treatment of xerostomia |
SM201400008T SMT201400008B (en) | 2009-11-12 | 2014-01-22 | Use of bethanecol for the treatment of xerostomia |
US14/842,297 US20150366794A1 (en) | 2009-11-12 | 2015-09-01 | Use of bethanechol for treatment of xerostomia |
US15/091,791 US10137084B2 (en) | 2009-11-12 | 2016-04-06 | Use of bethanechol for treatment of xerostomia |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0919822A GB0919822D0 (en) | 2009-11-12 | 2009-11-12 | The treatment of salivary gland dysfunction |
GB0919822.7 | 2009-11-12 | ||
GB1004445.1 | 2010-03-17 | ||
GBGB1004445.1A GB201004445D0 (en) | 2010-03-17 | 2010-03-17 | The treatment of salivary gland dysfunction |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/505,668 A-371-Of-International US9149454B2 (en) | 2009-11-12 | 2010-11-11 | Use of bethanechol for treatment of xerostomia |
US14/842,297 Continuation US20150366794A1 (en) | 2009-11-12 | 2015-09-01 | Use of bethanechol for treatment of xerostomia |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011058366A1 true WO2011058366A1 (en) | 2011-05-19 |
Family
ID=43382322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2010/051887 WO2011058366A1 (en) | 2009-11-12 | 2010-11-11 | Use of bethanechol for treatment of xerostomia |
Country Status (23)
Country | Link |
---|---|
US (3) | US9149454B2 (en) |
EP (1) | EP2498771B1 (en) |
JP (1) | JP5595513B2 (en) |
KR (1) | KR20120092152A (en) |
CN (1) | CN102711752B (en) |
AU (1) | AU2010317747B2 (en) |
BR (1) | BR112012011086A2 (en) |
CA (1) | CA2780256A1 (en) |
CY (1) | CY1114766T1 (en) |
DK (1) | DK2498771T3 (en) |
EA (1) | EA022040B1 (en) |
ES (1) | ES2443847T3 (en) |
HR (1) | HRP20140020T1 (en) |
IL (1) | IL219613A (en) |
MX (1) | MX2012005456A (en) |
NZ (1) | NZ599880A (en) |
PL (1) | PL2498771T3 (en) |
PT (1) | PT2498771E (en) |
RS (1) | RS53124B (en) |
SI (1) | SI2498771T1 (en) |
SM (1) | SMT201400008B (en) |
WO (1) | WO2011058366A1 (en) |
ZA (1) | ZA201203289B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012153110A1 (en) | 2011-05-06 | 2012-11-15 | Acacia Pharma Limited | Use of bethanechol for treatment of xerostomia |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7959598B2 (en) | 2008-08-20 | 2011-06-14 | Asante Solutions, Inc. | Infusion pump systems and methods |
GB2523989B (en) | 2014-01-30 | 2020-07-29 | Insulet Netherlands B V | Therapeutic product delivery system and method of pairing |
JP2018505756A (en) | 2015-02-18 | 2018-03-01 | インシュレット コーポレイション | Fluid delivery and infusion device and method of use thereof |
JP6472722B2 (en) * | 2015-06-30 | 2019-02-20 | サンスター株式会社 | Salivary secretagogue for oral administration |
EP3374905A1 (en) | 2016-01-13 | 2018-09-19 | Bigfoot Biomedical, Inc. | User interface for diabetes management system |
CA3009351A1 (en) | 2016-01-14 | 2017-07-20 | Bigfoot Biomedical, Inc. | Adjusting insulin delivery rates |
US10765807B2 (en) | 2016-09-23 | 2020-09-08 | Insulet Corporation | Fluid delivery device with sensor |
EP3568859A1 (en) | 2017-01-13 | 2019-11-20 | Bigfoot Biomedical, Inc. | Insulin delivery methods, systems and devices |
EP3749303A4 (en) * | 2018-02-05 | 2022-01-26 | Cellixbio Private Limited | Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof |
USD928199S1 (en) | 2018-04-02 | 2021-08-17 | Bigfoot Biomedical, Inc. | Medication delivery device with icons |
EP3788628A1 (en) | 2018-05-04 | 2021-03-10 | Insulet Corporation | Safety constraints for a control algorithm-based drug delivery system |
US11628251B2 (en) | 2018-09-28 | 2023-04-18 | Insulet Corporation | Activity mode for artificial pancreas system |
US11565039B2 (en) | 2018-10-11 | 2023-01-31 | Insulet Corporation | Event detection for drug delivery system |
WO2020138559A1 (en) * | 2018-12-28 | 2020-07-02 | 경상대학교병원 | Pharmaceutical composition and health functional food for prevention or treatment of hyposalivation |
USD920343S1 (en) | 2019-01-09 | 2021-05-25 | Bigfoot Biomedical, Inc. | Display screen or portion thereof with graphical user interface associated with insulin delivery |
US11801344B2 (en) | 2019-09-13 | 2023-10-31 | Insulet Corporation | Blood glucose rate of change modulation of meal and correction insulin bolus quantity |
US11935637B2 (en) | 2019-09-27 | 2024-03-19 | Insulet Corporation | Onboarding and total daily insulin adaptivity |
KR20210044714A (en) | 2019-10-15 | 2021-04-23 | 인하대학교 산학협력단 | New therapeutic composition using platelet rich plasma for the recovery of salivary gland dysfunction induced by aging |
EP4069082B1 (en) | 2019-12-06 | 2024-06-05 | Insulet Corporation | Techniques and devices providing adaptivity and personalization in diabetes treatment |
US11833329B2 (en) | 2019-12-20 | 2023-12-05 | Insulet Corporation | Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns |
US11551802B2 (en) | 2020-02-11 | 2023-01-10 | Insulet Corporation | Early meal detection and calorie intake detection |
US11547800B2 (en) | 2020-02-12 | 2023-01-10 | Insulet Corporation | User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system |
US11986630B2 (en) | 2020-02-12 | 2024-05-21 | Insulet Corporation | Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk |
US11324889B2 (en) | 2020-02-14 | 2022-05-10 | Insulet Corporation | Compensation for missing readings from a glucose monitor in an automated insulin delivery system |
US11607493B2 (en) | 2020-04-06 | 2023-03-21 | Insulet Corporation | Initial total daily insulin setting for user onboarding |
US11684716B2 (en) | 2020-07-31 | 2023-06-27 | Insulet Corporation | Techniques to reduce risk of occlusions in drug delivery systems |
WO2022080529A1 (en) * | 2020-10-15 | 2022-04-21 | 경상대학교병원 | Pharmaceutical composition and health functional food for preventing or treating hyposalivation |
US11904140B2 (en) | 2021-03-10 | 2024-02-20 | Insulet Corporation | Adaptable asymmetric medicament cost component in a control system for medicament delivery |
WO2023049900A1 (en) | 2021-09-27 | 2023-03-30 | Insulet Corporation | Techniques enabling adaptation of parameters in aid systems by user input |
US11439754B1 (en) | 2021-12-01 | 2022-09-13 | Insulet Corporation | Optimizing embedded formulations for drug delivery |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998009623A2 (en) * | 1996-09-03 | 1998-03-12 | Scotia Holdings Plc | Use of cholinergic drugs |
WO1998036733A2 (en) * | 1997-02-24 | 1998-08-27 | Michael Albert Kamm | Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker |
WO2007092811A2 (en) * | 2006-02-07 | 2007-08-16 | Whitehill Oral Technologies, Inc. | Sialagogue based oral care products |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9102340D0 (en) | 1991-08-13 | 1991-08-13 | Astra Ab | PHARMACEUTICAL COMPOSITION CONTAINING CARBACHOL AND OTHERCHOLINERGIC SUBSTANCES |
JP2683783B2 (en) | 1992-07-10 | 1997-12-03 | 雪印乳業株式会社 | Agent for Sjogren's syndrome |
US5766620A (en) | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
ZA9610154B (en) | 1995-12-12 | 1997-06-17 | Universiteit Van Preporia | Mouthwash |
US20080317679A1 (en) | 2002-10-25 | 2008-12-25 | Foamix Ltd. | Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses |
CA2677281C (en) | 2007-02-09 | 2019-10-29 | Durect Corporation | Transoral dosage forms comprising sufentanil and naloxone |
-
2010
- 2010-11-11 JP JP2012538414A patent/JP5595513B2/en not_active Expired - Fee Related
- 2010-11-11 MX MX2012005456A patent/MX2012005456A/en active IP Right Grant
- 2010-11-11 KR KR1020127015067A patent/KR20120092152A/en not_active Application Discontinuation
- 2010-11-11 EA EA201270619A patent/EA022040B1/en not_active IP Right Cessation
- 2010-11-11 WO PCT/GB2010/051887 patent/WO2011058366A1/en active Application Filing
- 2010-11-11 BR BR112012011086A patent/BR112012011086A2/en not_active Application Discontinuation
- 2010-11-11 PL PL10779033T patent/PL2498771T3/en unknown
- 2010-11-11 PT PT107790339T patent/PT2498771E/en unknown
- 2010-11-11 NZ NZ599880A patent/NZ599880A/en not_active IP Right Cessation
- 2010-11-11 US US13/505,668 patent/US9149454B2/en active Active
- 2010-11-11 EP EP10779033.9A patent/EP2498771B1/en active Active
- 2010-11-11 CN CN201080061277.5A patent/CN102711752B/en not_active Expired - Fee Related
- 2010-11-11 CA CA2780256A patent/CA2780256A1/en not_active Abandoned
- 2010-11-11 RS RS20140010A patent/RS53124B/en unknown
- 2010-11-11 DK DK10779033.9T patent/DK2498771T3/en active
- 2010-11-11 SI SI201030484T patent/SI2498771T1/en unknown
- 2010-11-11 ES ES10779033.9T patent/ES2443847T3/en active Active
- 2010-11-11 AU AU2010317747A patent/AU2010317747B2/en not_active Ceased
-
2012
- 2012-05-06 IL IL219613A patent/IL219613A/en not_active IP Right Cessation
- 2012-05-07 ZA ZA2012/03289A patent/ZA201203289B/en unknown
-
2014
- 2014-01-07 HR HRP20140020AT patent/HRP20140020T1/en unknown
- 2014-01-17 CY CY20141100044T patent/CY1114766T1/en unknown
- 2014-01-22 SM SM201400008T patent/SMT201400008B/en unknown
-
2015
- 2015-09-01 US US14/842,297 patent/US20150366794A1/en not_active Abandoned
-
2016
- 2016-04-06 US US15/091,791 patent/US10137084B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998009623A2 (en) * | 1996-09-03 | 1998-03-12 | Scotia Holdings Plc | Use of cholinergic drugs |
WO1998036733A2 (en) * | 1997-02-24 | 1998-08-27 | Michael Albert Kamm | Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker |
WO2007092811A2 (en) * | 2006-02-07 | 2007-08-16 | Whitehill Oral Technologies, Inc. | Sialagogue based oral care products |
Non-Patent Citations (14)
Title |
---|
BOROS ET AL., ARCHIVES OF ORAL BIOL., vol. 44, pages S59 - S62 |
CHAINANI-WU ET AL., SPEC. CARE DENTIST, vol. 26, no. 4, 2006, pages 164 - 170 |
CHAINANI-WU NITA ET AL: "Assessment of the use of sialogogues in the clinical management of patients with xerostomia", SPECIAL CARE IN DENTISTRY, AMERICAN DENTAL ASSOCIATION, CHICAGO, IL, US, vol. 26, no. 4, 1 July 2006 (2006-07-01), pages 164 - 170, XP009089350, ISSN: 0275-1879 * |
DAVIES ET AL., ORAL ONCOLOGY, vol. 38, 2002, pages 680 - 685 |
EPSTEIN JOEL B ET AL: "A clinical trial of bethanechol in patients with xerostomia after radiation therapy", ORAL SURGERY, ORAL MEDICINE, ORAL PATHOLOGY, MOSBY, ST LOUIS, MO, US, vol. 77, no. 6, 1 January 1994 (1994-01-01), pages 610 - 614, XP009142922, ISSN: 0030-4220 * |
FERGUSON, ARCHIVES OF ORAL BIOL., vol. 44, 1999, pages S11 - S14 |
JACOBSON ET AL., ORAL SURG ORAL MED ORAL PATHOL ORAL RADIOL ENDOD, vol. 81, 1996, pages 38 - 43 |
JENSEN ET AL., ORAL ONCOLOGY, vol. 44, 2008, pages 162 - 173 |
JHAM ET AL., ORAL ONCOL., vol. 43, 2007, pages 137 - 142 |
JHAM ET AL: "A randomized phase III prospective trial of bethanechol to prevent radiotherapy-induced salivary gland damage in patients with head and neck cancer", ORAL ONCOLOGY, ELSEVIER SCIENCE, OXFORD, GB, vol. 43, no. 2, 31 January 2007 (2007-01-31), pages 137 - 142, XP005893079, ISSN: 1368-8375, DOI: DOI:10.1016/J.ORALONCOLOGY.2006.01.013 * |
JOHN SMART: "Buccal Drug Delivery", EXPERT OPIN. DRUG DELIV., vol. 2, no. 3, 2005, pages 507 - 517 |
LOYD V ALLEN JR: "Bethanechol 5-mg/mL Oral Liquid", INTERNATIONAL JOURNAL OF PHARMACEUTICAL COMPOUNDING, IJPC, EDMOND, OK, US, vol. 9, no. 6, 1 November 2005 (2005-11-01), pages 473, XP009142934, ISSN: 1092-4221 * |
ONESCHUK ET AL., SUPPORT CARE CANCER, vol. 8, 2000, pages 372 - 376 |
ZANNI, PHARMACY TIMES, August 2007 (2007-08-01) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012153110A1 (en) | 2011-05-06 | 2012-11-15 | Acacia Pharma Limited | Use of bethanechol for treatment of xerostomia |
US9492546B2 (en) | 2011-05-06 | 2016-11-15 | Acacia Pharma Limited | Use of bethanechol for treatment of Xerostomia |
Also Published As
Publication number | Publication date |
---|---|
US20160287512A1 (en) | 2016-10-06 |
CN102711752B (en) | 2014-06-18 |
SMT201400008B (en) | 2014-03-07 |
RS53124B (en) | 2014-06-30 |
EP2498771B1 (en) | 2013-12-25 |
MX2012005456A (en) | 2012-06-19 |
SI2498771T1 (en) | 2014-04-30 |
KR20120092152A (en) | 2012-08-20 |
EA022040B1 (en) | 2015-10-30 |
EP2498771A1 (en) | 2012-09-19 |
EA201270619A1 (en) | 2012-12-28 |
CN102711752A (en) | 2012-10-03 |
HRP20140020T1 (en) | 2014-02-14 |
IL219613A0 (en) | 2012-07-31 |
ZA201203289B (en) | 2013-09-25 |
JP5595513B2 (en) | 2014-09-24 |
US20120232137A1 (en) | 2012-09-13 |
PL2498771T3 (en) | 2014-03-31 |
BR112012011086A2 (en) | 2016-07-05 |
AU2010317747A1 (en) | 2012-05-31 |
DK2498771T3 (en) | 2014-01-27 |
US9149454B2 (en) | 2015-10-06 |
US10137084B2 (en) | 2018-11-27 |
CA2780256A1 (en) | 2011-05-19 |
PT2498771E (en) | 2014-01-30 |
US20150366794A1 (en) | 2015-12-24 |
NZ599880A (en) | 2014-03-28 |
AU2010317747B2 (en) | 2013-10-17 |
IL219613A (en) | 2016-12-29 |
JP2013510840A (en) | 2013-03-28 |
CY1114766T1 (en) | 2016-12-14 |
ES2443847T3 (en) | 2014-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10137084B2 (en) | Use of bethanechol for treatment of xerostomia | |
US9532947B2 (en) | Formulation for oral transmucosal administration of analgesic and/or antispasmodic molecules | |
US20110021588A1 (en) | Sublingual dexmeditomidine compositions and methods of use thereof | |
EP2793857B1 (en) | Drug delivery technology | |
MXPA06009094A (en) | Controlled release formulations. | |
US20080138383A1 (en) | Compositions and methods for treating seizures | |
TW201818921A (en) | Acetaminophen and tramadol cosolvent compound analgesic oral liquid capable of solving the problem associated with using oral analgesic lozenges due to difficulties in swallowing | |
CA2747846C (en) | A formulation for the buccal transmucosal administration of setrons | |
US20230000796A1 (en) | Intranasal administration of ketamine to cluster headache patients | |
WO2020185214A1 (en) | Orally disintegrating tablets comprising glycopyrrolate and methods for increasing bioavailability | |
ES2738652T3 (en) | Compositions of midazolam for oral administration in the treatment of seizures to obtain rapid onset of action | |
US9492546B2 (en) | Use of bethanechol for treatment of Xerostomia | |
AU2020226862B2 (en) | Naloxone formulations for sublingual and/or buccal administration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080061277.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10779033 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010779033 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 219613 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2780256 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/005456 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010317747 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012538414 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2010317747 Country of ref document: AU Date of ref document: 20101111 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13505668 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201270619 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 20127015067 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012011086 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2014/0010 Country of ref document: RS |
|
ENP | Entry into the national phase |
Ref document number: 112012011086 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120510 |